

FORM PTO-1449
(REV. 7-80)

OCT 29 2010

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY DOCKET NO.

392.1001

APPLICATION NO

10/526,508

LIST OF PRIOR ART CITED BY APPLICANT

(Use several sheets if necessary)

APPLICANT

Hiroyuki ABURATANI, et al

FILING DATE

August 9, 2005

GROUP

1642

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
	A01					
	A02					

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
						Yes NO
	A03					
	A04					

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

A05	Ushiku et al., "Glypican 3-expressing gastric carcinoma: distinct subgroup unifying hepatoid, clear-cell, and alpha-fetoprotein-producing gastric carcinomas." Cancer Sci, vol. 100, no. 4, pgs. 626-632, April 2009	
A06	Yamanaka et al., "Immunohistochemical study of glypican 3 in thyroid cancer.", Oncology; 73: pgs. 389-394 (2007)	
A07	Okon et al., "Glypican-3 is expressed in chromophobe renal cell carcinomas.", Pol J. Pathol, 59, 1, pgs 15-20 (2008)	
A08	Maeda et al., "Glypican-3 expression in clear cell adenocarcinoma of the ovary." Modern Pathology 22, 824-832 (2009)	
A09	Aviel-Ronen et al., "Glypican-3 is overexpressed in lung squamous cell carcinoma, but not in adenocarcinoma.", Modern Pathology 21, 817-825 (2008)	
A10	Zynger et al., "Expression of glypican 3 in ovarian and extragonadal germ cell tumors.", Am J Clin Pathol; 130: 224-230, (2008)	
A11	Taketa et al., "A collaborative study for the evaluation of lectin-reactive alpha-fetoproteins in early detection of hepatocellular carcinoma.", Cancer Research 53, 5419-5423, November 15, 1993	
A12	Chan et al., "Evaluation of a monoclonal immunoenzymometric assay for alpha-fetoprotein.", Clin Chem. 32/7, 1318-1322 (1986)	
A13	Stephan et al., "Molecular forms of prostate-specific antigen and human kallikrein 2 as promising tools for early diagnosis of prostate cancer.", Cancer Epidemiology, Biomarkers and Prevention, Vol. 9, 1133-47, November 2000	
A14	Guess et al., "Benign prostatic hyperplasia and prostate cancer.", Epidemiologic Reviews, Vol. 23, No. 1, 2001	
A15	Jain et al., "Improving the utility of prostate specific antigen (PSA) in the diagnosis of prostate cancer: the use of PSA derivatives and novel markers.", Postgrad Med J.; 78: 646-650, (2002)	
A16	Nilsson et al., "Sensitivity and specificity of CA242 in gastro-intestinal cancer. A comparison with CEA, CA50 and CA 19-9.", Br. J. Cancer, 65, 215-221 (1992)	
A17	Pasanen et al., "Receiver operating characteristic (ROC) curve analysis of the tumour markers CEA, CA 50 and CA 242 in pancreatic cancer; results from a prospective study.", Br. J. Cancer, 67, 852-855 (1993)	
A18	Takada et al., "Measurement of cytokeratin 19 fragments as a marker of lung cancer by CYFRA 21-1 enzyme immunoassay.", British Journal of Cancer 71, 160-65, (1995)	
A19	Nisman et al., "Evaluation of urine CYFRA 21-1 for the detection of primary and recurrent bladder carcinoma.", American Cancer Society (2002), Vol. 94, No. 11, pgs. 2914-2922 (June 1, 2002)	

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.